Current Status of MicroRNA-Based Therapeutic Approaches in Neurodegenerative Disorders

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Jul 19

PMID 32679881

Citations 37

Authors

Sujay Paul

Luis Alberto Bravo Vazquez

Samantha Perez Uribe

Paula Roxana Reyes-Perez

Ashutosh Sharma

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are a key gene regulator and play essential roles in several biological and pathological mechanisms in the human system. In recent years, plenty of miRNAs have been identified to be involved in the development of neurodegenerative disorders (NDDs), thus making them an attractive option for therapeutic approaches. Hence, in this review, we provide an overview of the current research of miRNA-based therapeutics for a selected set of NDDs, either for their high prevalence or lethality, such as Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis, Friedreich's Ataxia, Spinal Muscular Atrophy, and Frontotemporal Dementia. We also discuss the relevant delivery techniques, pertinent outcomes, their limitations, and their potential to become a new generation of human therapeutic drugs in the near future.

Citing Articles

Mitochondrial microRNAs: Key Drivers in Unraveling Neurodegenerative Diseases.

Yashooa R, Duranti E, Conconi D, Lavitrano M, Mustafa S, Villa C Int J Mol Sci. 2025; 26(2).

PMID: 39859339 PMC: 11766038. DOI: 10.3390/ijms26020626.

Clinical value of miR-200b in diagnosis and prognosis of childhood pneumonia.

Qi W, Teng B, Zhang F, Chen Y, Xu J, Luan J BMC Pediatr. 2025; 25(1):42.

PMID: 39825267 PMC: 11748587. DOI: 10.1186/s12887-024-05370-1.

Unveiling the role of miR-186 in SIRT1 regulation in adipocytes: implications for adipogenesis and inflammation in obesity.

Tamkini M, Nourbakhsh M, Movahedi M, Golestani A J Diabetes Metab Disord. 2025; 24(1):42.

PMID: 39801683 PMC: 11711434. DOI: 10.1007/s40200-024-01525-0.

DNA Damage and Chromatin Rearrangement Work Together to Promote Neurodegeneration.

Sharma H, Koirala S, Chew Y, Konopka A Mol Neurobiol. 2024; 62(1):1282-1290.

PMID: 38977621 PMC: 11711770. DOI: 10.1007/s12035-024-04331-0.

MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.

Azam H, Rossling R, Geithe C, Khan M, Dinter F, Hanack K Front Mol Neurosci. 2024; 17:1386735.

PMID: 38883980 PMC: 11177777. DOI: 10.3389/fnmol.2024.1386735.

References

Blauwendraat C, Reed X, Kia D, Gan-Or Z, Lesage S, Pihlstrom L . Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurol. 2018; 75(11):1416-1422. PMC: 6248108. DOI: 10.1001/jamaneurol.2018.1885. View

Dong Y, Han L, Xu Z . Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson's disease. Mol Med. 2018; 24(1):61. PMC: 6263543. DOI: 10.1186/s10020-018-0059-9. View

Zhou Y, Lu M, Du R, Qiao C, Jiang C, Zhang K . MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol Neurodegener. 2016; 11:28. PMC: 4833896. DOI: 10.1186/s13024-016-0094-3. View

Goldman J, Van Deerlin V . Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. Mol Diagn Ther. 2018; 22(5):505-513. PMC: 6472481. DOI: 10.1007/s40291-018-0347-7. View

Keller A, Rounge T, Backes C, Ludwig N, Gislefoss R, Leidinger P . Sources to variability in circulating human miRNA signatures. RNA Biol. 2017; 14(12):1791-1798. PMC: 5731815. DOI: 10.1080/15476286.2017.1367888. View

Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J . MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?. Front Pharmacol. 2019; 10:665. PMC: 6591466. DOI: 10.3389/fphar.2019.00665. View

Koeppen A . Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011; 303(1-2):1-12. PMC: 3062632. DOI: 10.1016/j.jns.2011.01.010. View

Wen Z, Zhang J, Tang P, Tu N, Wang K, Wu G . Overexpression of miR‑185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson's disease. Mol Med Rep. 2017; 17(1):131-137. PMC: 5780076. DOI: 10.3892/mmr.2017.7897. View

Chen-Plotkin A, Unger T, Gallagher M, Bill E, Kwong L, Volpicelli-Daley L . TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci. 2012; 32(33):11213-27. PMC: 3446826. DOI: 10.1523/JNEUROSCI.0521-12.2012. View

10.

Khodr C, Becerra A, Han Y, Bohn M . Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 2014; 1550:47-60. PMC: 3974902. DOI: 10.1016/j.brainres.2014.01.010. View

11.

Miniarikova J, Zimmer V, Martier R, Brouwers C, Pythoud C, Richetin K . AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. Gene Ther. 2017; 24(10):630-639. PMC: 5658675. DOI: 10.1038/gt.2017.71. View

12.

Her L, Mao S, Chang C, Cheng P, Chang Y, Yang H . miR-196a Enhances Neuronal Morphology through Suppressing RANBP10 to Provide Neuroprotection in Huntington's Disease. Theranostics. 2017; 7(9):2452-2462. PMC: 5525749. DOI: 10.7150/thno.18813. View

13.

Saraiva C, Ferreira L, Bernardino L . Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson's disease. Neurogenesis (Austin). 2017; 3(1):e1256855. PMC: 5384609. DOI: 10.1080/23262133.2016.1256855. View

14.

Qiu L, Tan E, Zeng L . microRNAs and Neurodegenerative Diseases. Adv Exp Med Biol. 2015; 888:85-105. DOI: 10.1007/978-3-319-22671-2_6. View

15.

Lin H, Nikolic I, Yang J, Castillo L, Deng N, Chan C . MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci Rep. 2018; 8(1):7820. PMC: 5959911. DOI: 10.1038/s41598-018-26050-y. View

16.

Shi Z, Zhang K, Zhou H, Jiang L, Xie B, Wang R . Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer's Disease. Aging Cell. 2020; 19(3):e13125. PMC: 7059146. DOI: 10.1111/acel.13125. View

17.

Ansari A, Rahman M, Saha S, Saikot F, Deep A, Kim K . Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell. 2016; 16(1):4-16. PMC: 5242307. DOI: 10.1111/acel.12538. View

18.

Piscopo P, Albani D, Castellano A, Forloni G, Confaloni A . Frontotemporal Lobar Degeneration and MicroRNAs. Front Aging Neurosci. 2016; 8:17. PMC: 4746266. DOI: 10.3389/fnagi.2016.00017. View

19.

Aarsland D, Creese B, Politis M, Chaudhuri K, Ffytche D, Weintraub D . Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13(4):217-231. PMC: 5643027. DOI: 10.1038/nrneurol.2017.27. View

20.

Callister J, Pickering-Brown S . Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol. 2014; 262 Pt B:84-90. PMC: 4221591. DOI: 10.1016/j.expneurol.2014.06.001. View